Skip to content

Author

Niangmei Cheng

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Jul 2026

p53-R280S mutation confers lenvatinib resistance in hepatocellular carcinoma via Bcl-2-mediated anti-apoptotic signaling.

Lenvatinib is approved as a first-line treatment for patients with unresectable hepatocellular carcinoma (HCC), however, its clinical efficacy is frequently limited by the emergence of drug resistance. This study aimed to elucidate the underlying mechanisms by which HCC develops resistance to lenvatinib. Lenvatinib-res...

Niangmei Cheng, Kexin Liu, Xin Qi et al. · 0 citations
Open access Jul 2026

LncRNA MKRN3-AS1 promotes metastasis and autophagy of hepatocellular carcinoma by sponging multiple microRNAs.

Hepatocellular carcinoma is one of the most common malignant tumors with poor clinical outcomes. Increasing numbers of long noncoding RNAs have been shown to be involved in the carcinogenesis and progression of HCC. However, the expressions, clinical significances, and roles of most lncRNAs in HCC are still unknown. In...

Fei Wang, Ji-Zhe Liu, Gaoxiong Wang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.